BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211115
DTEND;VALUE=DATE:20211117
DTSTAMP:20260515T223747
CREATED:20210608T113322Z
LAST-MODIFIED:20210608T113525Z
UID:30480-1636934400-1637107199@www.pharmajournalist.com
SUMMARY:Medical Devices and IVD conference 2021
DESCRIPTION:Navigating new legislations and strategies to comply with regulatory requirements \nSMi is proud to announce the launch of their Medical Devices and IVD conference to be held in London in November 2021. \nThe MDR and IVDR updates will have a profound impact on the medical device industry\, bringing certain products into regulatory scope that were previously excluded\, introducing new manufacturing requirements\, and increasing the burden for post-market surveillance. What does this mean for the future of the Medical Devices and IVD industry? \nSMi’s inaugural Medical Devices and IVD conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these new regulations. In addition\, the conference will examine MHRA Guidance on Post-Brexit IVD Regulations and consider the evolving regulatory landscape for digital health software. Join Europe’s leading Medical Device and IVD Conference which will address post-market surveillance and vigilance\, clinical evaluations and investigations\, medical device regulatory affairs in global markets\, and much more. \n \nBENEFITS OF ATTENDING: \n\nEngage with notified body and competent authority representatives addressing key MDR and IVDR requirements\nGain insights from pharma regulatory experts in compliance and companion diagnostics\nUnderstand the latest guidance on Post-Brexit IVD Regulations to overcome common challenges\, in addition to considering evolving global regulations\nExamine post-market expectations for surveillance and vigilance of your medical devices\nDelve into how COVID-19 has impacted the MDR and IVD regulations\n\nView the full agenda and speaker line-up online: www.medicaldevices-ivd.com/pjwl \nPlus\, post-conference workshop will be taking place on 17th November in London: \nImplementing the EU MDR and Article 117\, An Industry Perspective \nWorkshop Leader: Blake Green\, Senior Manager Regulatory Affairs\, Amgen \nEARLY-BIRD RATES: \n\nBOOK BY 30TH JUNE AND SAVE £200\nBOOK BY 30TH SEPTEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.medicaldevices-ivd.com/pjwl \nCHAIR FOR 2021: \nAndreas Stange\, Vice President\, TÜV SÜD \nHEAR FROM EXPERT INDUSTRY SPEAKERS: \n\nJessica Wilkerson\, Cyber Policy Advisor\, FDA\nSusan Neadle\, Executive Director\, Combination Products\, Devices\, Diagnostics & Digital Health Regulatory Affairs\, Amgen\nClaudia Dollins\, Head\, Precision Medicine & Companion Diagnostics\, Bristol Myers Squibb\nMichael Benecky\, Senior Director\, Global Regulatory Affairs\, UCB Biosciences\nChristophe Driesmans\, Head of the Materiovigilance Entity\, Federal Agency for Medicines and Health Products (FAMHP)\nMelanie Donguy\, Head Regulatory Affairs EMEA\, Bayer Radiology\nMarc Moal\, Head of Product Delivery & Project Management\, Merck Connected Health & Devices\nJim Leamon\, Director of Biologics Device Development\, Jazz Pharmaceuticals\nLouise Place\, Director\, Devices\, GlaxoSmithkline\nStefan Strasser\, Head of Department\, Austrian Medicines and Medical Devices Agency
URL:https://www.pharmajournalist.com/event/medical-devices-and-ivd-conference-2021/
LOCATION:London\, UK | Virtual Attendance Option Available
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223747
CREATED:20210809T105337Z
LAST-MODIFIED:20210809T105337Z
UID:31259-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
DESCRIPTION:In the unprecedented array\, and steady stream of novel\, topical\, and systemic agents entering various phases of drug development\, for critical inflammatory and autoimmune dermatological conditions this year\, the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases\, returns to Boston for 2021. As the world’s leading\, and only forum committed to overcoming significant R&D hurdles\, and sharing of best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions\, this forum is not to be missed. \nWith the rising demand for consolidation and precision medicine\, along with multiple new agents edging closer to market for Atopic Dermatitis towards the end of the year\, the 5th annual meeting addresses advances and challenges in genetic discoveries\, antibody drug development\, delivery strategies and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe\, inflammatory skin conditions. \nEnsure you join this year’s 150+ expert community\, in-person\, to uncover recent studies evaluating critical inflammatory and auto-immune pathways\, gain a deeper understanding of promising biologics targeting IL-13\, IL-31\, IL-33\, whilst continuing to assess emerging efficacious targeted approaches when developing safer treatments to patients with debilitating skin diseases. Additionally\, obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet need such as Hidradenitis Suppurativa and Vitiligo. \nLeave this year’s meeting having overcome innovative modelling challenges by gaining simulation tools/strategies to support your clinical drug development pipeline\, evaluate optimal dose and dosing regimen to support formulation changes for your approach\, whilst having debated what makes a dermatology investment most successful when advancing therapies for inflammatory and autoimmune skin conditions to market. \nTo find out more visit: https://ter.li/e93ads
URL:https://www.pharmajournalist.com/event/5th-annual-dermatology-drug-development-summit-for-inflammatory-skin-diseases/
LOCATION:Hilton Boston/Woburn\, 2 Forbes Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223747
CREATED:20210812T114547Z
LAST-MODIFIED:20210812T114547Z
UID:31287-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:3rd Inflammasome Therapeutics Summit
DESCRIPTION:Discover the Intricacies of Inflammasome Regulation\, Leverage Inflammasome Proteins as Biomarkers & Accelerate Novel Inflammasome Therapeutics into Proof-Of-Concept Clinical Trials & Beyond \nBuilt with Ventus Therapeutics\, Inflammasome Therapeutics\, Merck & more\, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel inflammasome therapeutics into proof of-concept clinical trials and beyond! \nWith a plethora of inflammasome-targeted drugs poised to enter the clinic in 2021\, this year’s summit will once again unite thought leaders in inflammasome drug development. \nExpect to be involved in interactive discussions on: \n\nHow dysregulated inflammasome activation\, formation and signaling contributes to disease and how to identify novel drug targets beyond NLRP3\nThe interface of inflammasome signaling with innate immunity\, microbial interactions\, metabolism\, neuroimmune and other systems\nLeveraging inflammasome proteins in precision-based medicine as disease biomarkers and companion diagnostics in both the preclinical and clinical setting\nIdentifying and translating the most promising therapeutic applications of inflammasome-targeted drugs across monogenic diseases\, as well as infectious\, ophthalmic\, neurological and cancer settings\n\nThis year’s meeting has two parallel tracks of learning with 30+ speakers sharing highly anticipated case studies. As the growth potential of novel inflammasome therapeutics becomes apparent\, join the conversation to validate novel inflammasome targets beyond NLRP3 and realize the clinical and commercial potential of inflammasome proteins across different diseases! \nTo Know more visit: https://ter.li/bdw0tf
URL:https://www.pharmajournalist.com/event/3rd-inflammasome-therapeutics-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223747
CREATED:20210903T051305Z
LAST-MODIFIED:20210903T051305Z
UID:31548-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:3rd Exosome Based Therapeutic Development Summit
DESCRIPTION:The 3rd Exosome-Based Therapeutic Development Summit returns with a more comprehensive agenda than ever before\, reuniting leading pharma\, biotech\, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine\, autoimmunity\, COVID-19 and beyond. \nDeep diving into the key challenges such as sourcing\, characterization\, cargo loading\, manufacturing and clinical development\, this year’s summit will be your comprehensive roadmap to realizing\, strategizing and advancing the full therapeutics and drug delivery opportunities offered by exosomes. \nTailor-made to showcase the latest innovations and interactively discuss the industry’s most important talking points\, join leading biopharmaceutical Directors\, VPs and C-Level Executives to successfully optimize\, accelerate and scale your exosome-based therapeutics as next generation drugs for unmet clinical needs \nKey Highlights: \n\nShining a spotlight on orally delivered bacterial extracellular vesicles with unique pharmacological profiles with striking anti-inflammatory effects\, an exciting new approach for exosome therapeutics with Evelo Biosciences\n\n\nDeep dive into the latest data coming out of the clinic with key learnings from phase I/II trials of Covid-19\, oesteoarthirtus and gastrointestinal diseases with insights from Organicell\, University of Athens & University of Louisville\n\n\nNavigating the complex regulatory landscape for exosomes to understand what the FDA requires to progress through each development stage and the potential for successful applications into 2021 with insights from Rion\n\n\nExploring proteomic insights in understanding EVs and the mechanisms of action of EV-mediated RNA delivery to enable more efficient and efficacious exosome therapies with Exogenus Therapeutics Aruna Bio\, Stem XO & Baker Heart and Diabetes Institute\n\n\nExpanding the boundaries of engineering exosomes including cell selection\, applications of the technology\, monitoring biodistribution and enabling direct delivery with Exogenus VivaZome Therapeutics\, OmniSpriant & Exogenus Therapeutics\n\nTo know more visit: https://ter.li/h99vsb
URL:https://www.pharmajournalist.com/event/3rd-exosome-based-therapeutic-development-summit/
LOCATION:Digital Event\, EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR